Back to search page

rdit20170524003

Research grant - companies involved in the development and commercialization of pharmacogenomic and companion diagnostic tests.

RESEARCH PROFILE   REQUEST   ADD TO FAVOURITES
PRINT

 

ABSTRACT

An Italian research group has developed a diagnostic kit for the detection of “responders” to biologic drugs for rheumatoid arthritis. They are looking for research collaborations with companies that produce pharmacogenomic and companion diagnostic tests. A regional grant can support the co-development of the research results by paying the costs of one year research fellowship.


FULL DESCRIPTION

An Italian research grupo has developed a personalized therapy for rheumatoid arthritis. Recently, some biologic drugs with high potential in controlling the effects of rheumatoid arthritis have been developed. Such drugs have high costs and are not effective on the entire rheumatoid arthritis patients population. Therefore, the development of strategies to predict the clinical response to such drugs is needed, in order to select rapidly and on a large scale those patients who will benefit from the therapy. The proposed technology consists of an innovative kit for the identification of “responders” to the new biologic drugs for the treatment of rheumatoid arthritis.

They are looking for research collaboration with companies involved in the development and commercialization of pharmacogenomic and companion diagnostic tests to co-develop the research results.

This diagnostic kit will integrate gene expression analysis with procedures that allow enriching of the cell types responsible for the production of inflammatory molecules, thus providing a test with a greater predictive power than the basic whole blood analysis.

Deadline of the call: 30/08/2017
Deadline for EoIs: 15/07/2017


Partner expertise sought:

- Specific area of activity of the partner: Type: companies involved in the development and commercialization of pharmacogenomic and companion diagnostic tests.

Role: co-development of the research results.


Advantages & innovations:

A pharmacogenetics tool for rheumatoid arthritis biologic drugs will not only help to select patients that would definitely benefit from the drug, but will also assist in revealing the right dose for individual patients, saving a lot of money for the healthcare system. Furthermore, the ability to assess an individual's reaction to a drug before it is prescribed will increase a physician's confidence in prescribing the drug and the patient's confidence in taking the drug itself.

Sign-in or create an account

To express an interest in this profile, you must first sign in or create a new account.

If you already have an account, sign in here

Not got an account yet, sign up here

KEY INFORMATION

Country of origin
ITALY
Profile date
26/06/2017
Deadline
26/06/2018

PARTNERSHIP(S) SOUGHT

Research cooperation agreement

CLASSIFICATIONS

INDUSTRY SECTORS
Life Sciences \ Biosciences and Health \ Drug Discovery and Drug Development \ Diagnostics \ Medical Devices
TECHNOLOGY KEYWORDS
BIOLOGICAL SCIENCES / Medicine, Human Health / Diagnostics, Diagnosis / BIOLOGICAL SCIENCES / Biology / Biotechnology / Cellular and Molecular Biology / BIOLOGICAL SCIENCES / Biology / Biotechnology / In vitro Testing, Trials / BIOLOGICAL SCIENCES / Genome Research / Gene Expression, Proteome Research
COMMERCIAL KEYWORDS
Research and experimental development on biotechnology
MARKET KEYWORDS
GENETIC ENGINEERING/MOLECULAR BIOLOGY / Cellular and Molecular Biology / GENETIC ENGINEERING/MOLECULAR BIOLOGY / In vitro Testing, Trials / GENETIC ENGINEERING/MOLECULAR BIOLOGY / Gene Expression, Proteome Research / MEDICAL/HEALTH RELATED / Diagnostic / In-vitro diagnostics

FIND OUT MORE

Contact Enterprise Europe Network Scotland by email at info@enterprise-europe-scotland.com, quoting reference number rdit20170524003